ClinicalTrials.gg
RecruitingNCT05681455Updated Jun 6, 2023

Physiotherapy for Persistent Function by Superficial Neuromodulation

An interventional study of Neuromodulation NESA NXSIGNAL® device in Post-Acute COVID-19 Syndrome, Dysautonomia and Neuromodulation, sponsored by Universidad Rey Juan Carlos. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Universidad Rey Juan Carlos · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
35th of 39
24 · median 60
Started
2023
with 11 others
No phase
31 of 52
7 open now
Primary completion
2023-06
later than 0 of 15 live
Registered
16th of 52
by date
Lead sponsor
2 of 52
Universidad Rey Juan Carlos

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 35th largest by planned enrollment of the 39 interventional ones that give a count, is one of 12 that started in 2023, is one of 31 with no phase, reaches primary completion later than 0 of the 15 other live ones, and was the 16th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Objectives:

To evaluate pressure pain thresholds, fatigue scales, quality of life and sleep quality, in women with Persistent Covid (PC), pre- and post-treatment using electrotherapy and in a placebo group of PC patients.

Relevance:

This trial can be a tool for patients affected by CP who present pain and fatigue problems, insomnia or signs of imbalance of their Autonomic Nervous System. It aims to improve their rest and recovery for a better quality of life that allows them to recover their Activities of Daily Living.

We have designed the study with a commitment to placebo group treatment after completion, if positive results are obtained.

A 6-month and 1-year follow-up will be scheduled.

Secondary objectives:

To analyze the effects on quality of life, fatigue and sleep. To analyze the presence of cardiac variability and pre- and post-treatment cortisol values.

Patients and Methods:

12 patients with CP will receive 15 sessions of electrotherapy. 12 will receive a placebo.

Mechanical sensitivity pre-post, by means of an algometer, cardiac variability, cortisol levels, and other variables, will be measured by means of questionnaires.

Mechanical sensitivity to pain will be measured using an algometer (Baseline 12-0300 MMT). Patients will be instructed to report when the sensation of pressure changes to pain.

The pre-post electrotherapy treatment described above will be measured, the differences in mechanical sensitivity, pain threshold to pressure, the Pittsburg questionnaires, SF-36, MFIS and EQooL-5.

Follow-up will be done at 6 months and at one year. The study design is a triple-blind randomized controlled clinical trial. Patients who sign the consent form will be evaluated by an internist who will perform a physical examination at the clinic of the Faculty of Nursing and Physiotherapy of the Pontifical University of Salamanca (UPSA).

The sample will be randomized. 12 patients will receive treatment and 12 patients will receive a placebo. With a commitment to treat these patients in the event that positive results are obtained after the end of the study.

A biphasic microcurrent will be applied with a frequency between 1.14 Hertz and 14.29 Hertz and intensities between 0.1 and 0.9 mA.

Frequency: 2 times a week. A total of 15 sessions in 7.5 weeks. The session time with microcurrents will last 60 minutes.

.

03

Conditions studied

  • Post-Acute COVID-19 Syndrome
  • Dysautonomia
  • Neuromodulation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who have had symptoms of PC for more than one year.
  • Signs of central sensitization.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with surgery.
  • Previous spinal trauma.
  • Whiplash.
  • Pregnancy situation.
  • Previous musculoskeletal disease (rheumatoid arthritis, sympathetic-reflex dystrophy, fibromyalgia).
  • Pacemaker.
  • Electric drug pump.
  • Skin sensitivity alterations.
  • Analgesic or anxiolytic drug treatment during the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Experimental group

    A two-phase microcurrent with a frequency between 1.14 Hertz and 14.29 Hertz and currents between 0.1 and 0.9 mA will be applied. A total of 15 sessions in 7.5 weeks. Twice a week. The session time with microcurrents will last 60 minutes.

    Device: Neuromodulation NESA NXSIGNAL® device

  • Placebo comparator
    Placebo group

    Microcurrent machines shall be operated in such a way that they have a light signal but do not emit current. Neither the physical therapists who place them nor the subjects will be able to distinguish current-emitting machines from placebo machines. A total of 15 sessions in 7.5 weeks. Twice a week. The session time with placebo will last 60 minutes.

    Device: Neuromodulation NESA NXSIGNAL® device

Interventions

  • DeviceNeuromodulation NESA NXSIGNAL® device

    Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®. The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire. The directional electrode will be placed in the cervical area at the superficial level between C6 and C7.

06

What researchers measure

Primary outcomes

  1. Pain Pressure Threshold

    Central sensitization by assessment of the Pressure Pain Threshold (PPU) in kg: Baseline 12-0300 MMT algometer at cervical C5-C6, dorsal D5-D6 and anterior tibial muscle.

    Time frame: Change from Baseline Pain Pressure Threshold at 1 year

Secondary outcomes

  1. Quality of life RELATED TO HEALTH

    SF-36 questionnaire

    Time frame: Change from baseline quality of life related to health at 1 year

  2. Quality of life RELATED TO HEALTH

    EuroQool-5-D questionnaire

    Time frame: Change from baseline quality of life related to health at 1 year

  3. effects on fatigue

    MFIS questionnaire (Modificated Fatigue Impact Scale)

    Time frame: Change from Baseline fatigue at 1 year

  4. Quality of sleep

    Pittsburg questionnaire

    Time frame: Change from Baseline Quality of Sleep at 1 year

  5. cardiac variability

    HRV (cardiac variability)" in ms 2. "SDNN (Standard deviation of all R-R intervals)" in ms 3. "rMSSD (Root mean square of the union of adjacent R-R intervals)" in ms

    Time frame: Change from Baseline Cardiac variability at 1 year

  6. Cortisol levels

    Soma OFCII cube device in nmol/L

    Time frame: Change from Baseline Cortisol level at 1 year

07

Study locations

1 of 1 sites recruiting
  • Department of Physiotherapy, Occupational Therapy, Rehabilitation and Physical Medicine. Faculty of Health Sciences. Rey Juan Carlos University
    Alcorcón, Madrid, Spain
    Recruiting
    • Sofía Laguarta-Val, PhD · Contactsofia.laguarta@urjc.es · 00344888662
    • Sofía Laguarta-Val, PT,MsC,PhD · Principal investigator
    • Alberto Melián-Ortiz, PT,MsC,PhD · Sub investigator
    • Josué Fernández-Carnero, PT,MsC,PhD · Sub investigator
    • Carmen Jiménez-Antona, PT,MsC,PhD · Sub investigator
08

References and documents

Publications

  • Gaber TAK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. Occup Med (Lond). 2021 Jun 16;71(3):144-146. doi: 10.1093/occmed/kqab043. PubMed 33830208 ↗
  • Burgess LC, Venugopalan L, Badger J, Street T, Alon G, Jarvis JC, Wainwright TW, Everington T, Taylor P, Swain ID. Effect of neuromuscular electrical stimulation on the recovery of people with COVID-19 admitted to the intensive care unit: A narrative review. J Rehabil Med. 2021 Mar 18;53(3):jrm00164. doi: 10.2340/16501977-2805. PubMed 33634830 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Jun 2023, 0 months later.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 0 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Jan 12, 2023
StartEst.
Jun 15, 2023
Primary completionEst.
Jun 15, 2023
CompletionEst.
Jul 30, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05681455
Responsible party
Josue Fernandez Carnero (Physiotherapy for Persistent Function by Superficial Neuromodulation, Universidad Rey Juan Carlos) — Principal investigator
First posted
Jan 12, 2023
Start date
Jun 15, 2023 (estimated)
Primary completion
Jun 15, 2023 (estimated)
Completion
Jul 30, 2023 (estimated)
Last update
Jun 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion